Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07371104 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Feb 20, 2026 to Apr 22, 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2026 to Feb 20, 2026v3 Show 1 more changeShow less
    • Start date changed from estimate of Jan 2026 to Feb 20, 2026
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer
Trial Details
NCT Number NCT07371104
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Cancer, Ovarian Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov